Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $153,356.49 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 24,381 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $6.29, for a total value of $153,356.49. Following the sale, the chairman owned 3,512,822 shares of the company’s stock, valued at approximately $22,095,650.38. The trade was a 0.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.63, for a total value of $132,600.00.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total value of $44,540.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $5.76 on Friday. The firm has a 50 day moving average of $5.45 and a 200-day moving average of $5.09. The company has a market cap of $483.21 million, a price-to-earnings ratio of -11.08 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.77.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. On average, equities analysts forecast that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of research analyst reports. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th. HC Wainwright assumed coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the first quarter valued at about $2,157,000. Royce & Associates LP purchased a new position in SOPHiA GENETICS during the fourth quarter worth about $2,009,000. Finally, Sei Investments Co. bought a new stake in SOPHiA GENETICS in the 1st quarter worth about $1,772,000. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.